Related Experiment Video
Updated: Sep 23, 2025
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
379
Case Report: Long-Acting Oral Cariprazine
Emanuela Dyrmishi1, Marco De Pieri2,3, Marco Ferrari3
1Organizzazione Sociopsichiatrica Cantonale, Mendrisio, Switzerland.
Frontiers in Psychiatry
|May 16, 2022
Summary
Cariprazine, an antipsychotic, effectively treated bipolar I disorder and schizoaffective disorder in outpatients when administered twice weekly. This dosing regimen demonstrated sustained remission and treatment response, offering an "oral long-acting" alternative.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Cariprazine is a third-generation antipsychotic used for schizophrenia and bipolar disorder.
- It acts as a partial agonist at dopamine D2/D3 and serotonin 5HT1A receptors, and antagonist at 5HT2B/2A receptors.
- Cariprazine has active metabolites with long half-lives (1-2 days and 2-3 weeks).
